Skip to main content
Sign In
 

PhD in Pharmaceutical Sciences, Pharmaceutical Outcomes Research Track

Current Students


​​PhD Students (L to R): Chong H Kim (entered 2015), Katie Sullivan (entered 2013), David Tabano (entered 2013), Robert Perry (entered 2014), Mausam Patidar (entered 2015).




Mau sam Patidar: Analyzing the prescription of anti-depressants and incidence of Depression among patients with Irritable Bowel Syndrome using administrative claims data. Assessing the adherence of metformin in children (age 10-18) in comparison to adults using the PharMetrics data.

Chong Kim (CK) was born in East Lansing Michigan and spent most of his time in Michigan until he graduated in 2009 with a BS in Biochemistry from the Michigan State University. He went on to receive his MPH in Health Policy and Management from the Columbia University Mailman School of Public Health in 2013. He worked as a junior analyst in Korea, identifying cost-effective therapies for ovarian cancer and Cushing's disease, such that formulary decisions could be updated. CK started the PhD program in Pharmaceutical Outcomes Research in fall 2015 and has been interested in utilizing machine learning and statistical models to determine the impact of short-acting beta-agonist on clinical and economic outcomes of asthma patients. CK has a website featuring some of the research he's doing. 


Robert Perry: I’m currently in my second year and have really enjoyed my studies thus far. My research interests include mental health outcomes, psychiatric drug treatment, and validation of patient-reported outcome measures. I’m currently investigating antidepressant utilization in Irritable Bowel Syndrome and investigating methods for enhancing early detection of opioid misuse.


David Tabano: I am currently working on my dissertation thesis, which aims to understand the prevalence of chronic Hepatitis C, the progression of the disease and measurable treatment outcomes in a multi-site regional network in Colorado. 


Katherine Sullivan: I am currently working on my dissertation in which I am looking at the associations between medications (i.e. prescription and over the counter) and Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, which are rare adverse drug reactions.


Katia Hannah is a Washington State native. She graduated from Washington State University with a BS in Zoology in 2010. She then moved to Colorado to attend Colorado School of Public health, completing both the Certificate and Masters in Public Health programs with a focus in epidemiology. During the master's program, she worked with Dr. Rob Valuck and Dr. Heather Anderson on her capstone project studying the association between anticholinergic toxicity and adverse health outcomes using measures of toxicity generated by three anticholinergic toxicity scales. She joined the CePOR program in fall 2016 and is currently conducting health outcomes research focusing on Epinephrine Auto-Injectors with Dr. Robert Brett McQueen.



Kimberly Deininger was born and raised in Cleveland, Ohio.  She graduated from Case Western Reserve University with a BS in Biology in 2006.  During this time, she conducted research related to pioglitazone and ischemic stroke in a rat model.  She then moved to Colorado, where she attended the Colorado School of Public Health, completing the MPH program with a focus in epidemiology in 2015.  She worked with Dr. Christina Aquilante on her master’s capstone research studying the clinical utility of a pharmacogenomic screening prior to cardiac transplantation.  Post-graduation, she continued with pharmacogenomics research as a research coordinator in Dr. Aquilante’s lab.  She joined the POR program in 2016 and continues to conduct pharmacogenomics research focusing on patient-related and clinical outcomes in transplant in Dr. Aquilante’s lab.

 

Why CU's Pharmaceutical Outcomes Research PhD track?

Mausam Patidar: After completing my Masters, I wanted to get into the program and be a part of the projects which could have a direct impact on policy issues and patients outcomes. When I got the offer, I had no doubts about joining this program where the engaging research component in this program is evident by the outstanding faculties. This program with its excellent infrastructure, curriculum and research platform was a perfect academic place for my ambitions, an opportunity that will allow me to carve a unique niche in this field.

Chong Kim: There were several factors that ultimately led me to choose POR training program. The biggest factor was the research output from alumni. Although individual capacity may determine the amount of research that may be done, I felt that at least everyone had enough exposure to opportunities to contribute in various projects that the faculty were a part of. Another factor was the prospects for future career. Some of the alumni graduated to take the academic route, some took on the industry route. What allowed me to be at ease of mind was the fact that none of them had difficulty in job searching and were doing quite well due to the opportunities (research and networking) they had during their stay in the program. I’ve been involved in several projects throughout my first and second semester and I know I’ve definitely made the best choice in coming to this program based on just that.

Robert Perry: I was interested in getting into an applied area of science related to my interests in addiction and psychiatric drug research. I love the State of Colorado and was aware of a number of interesting projects at UC Denver in Pharmaceutical Outcomes Research. I am glad to say it has worked out as envisioned.

David Tabano: My academic background in economics, and I have worked in the healthcare industry from the past seven years, first in healthcare policy and currently in healthcare research. The POR PhD track is a fantastic program because it blends health economics with comparative effectiveness research so well. I chose to enroll in at University of Colorado because the program fit my academic and professional interests so well, and because of the awesome learning environment. The student-faculty ratio is incredibly low, making POR faculty not only accessible but genuinely invested in their students. The resources available to students in this program are very useful, both for coursework and for independent research.

Katherine Sullivan: I enrolled in the POR PhD training track because I was, and still am, interested in how pharmaceuticals influence people's daily lives. From the broader policy level to the specific medications that people take, pharmaceuticals have a huge impact on human health. I have also always been interested in research at the population level. I started as an undergraduate in Ecology studying how environmental factors, including pharmaceuticals in the water systems, influence animal population health. After that, I became interested in how pharmaceuticals might be influencing human populations, which led me to the POR program at CU Anschutz, where I have specialized in pharmacoepidemiology. The friendly faculty and smaller size of the program also made it very easy for me to decide that the POR program was the right fit for me.

PhD Student Research Projects